Comparative Pharmacology
Head-to-head clinical analysis: LIDOCAINE VISCOUS versus PEDIATRIC LTA KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIDOCAINE VISCOUS versus PEDIATRIC LTA KIT.
LIDOCAINE VISCOUS vs PEDIATRIC LTA KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lidocaine is an amide-type local anesthetic that blocks voltage-gated sodium channels (Nav1.7, Nav1.8) in neuronal membranes, inhibiting depolarization and propagation of action potentials, thereby producing local anesthesia. It also has antiarrhythmic properties (class IB) by blocking sodium channels in cardiac myocytes.
PEDIATRIC LTA KIT contains lidocaine, tetracaine, and epinephrine. Lidocaine and tetracaine are amide and ester local anesthetics, respectively, that block voltage-gated sodium channels, preventing nerve impulse propagation. Epinephrine is a sympathomimetic that causes vasoconstriction, prolonging local anesthetic effect and reducing systemic absorption.
15 mL (300 mg) orally every 3 hours as needed for pain; maximum 8 doses per 24 hours.
Not applicable. Pediatric LTA Kit is a topical lidocaine/tetracaine patch for dermal anesthesia. Adult dose: apply one patch to intact skin for 20-30 minutes prior to procedure; remove prior to procedure. Maximum 3 patches per session. Not for systemic use.
None Documented
None Documented
Terminal elimination half-life is 1.5–2 hours (up to 3 hours in hepatic impairment). Clinically, redistribution half-life (~6 min) determines duration of action after short infusions.
2-3 hours (terminal) in children with normal renal function; prolonged in renal impairment
Renal excretion of unchanged drug and metabolites accounts for >90% of elimination; <10% biliary/fecal. Metabolites include monoethylglycinexylidide (MEGX) and glycinexylidide (GX).
Renal (95% as unchanged drug), fecal (5%)
Category A/B
Category C
Local Anesthetic / Antiarrhythmic (Class Ib)
Local Anesthetic